Tandem Historical Income Statement
| TNDM Stock | USD 31.73 1.30 4.27% |
Historical analysis of Tandem Diabetes income statement accounts such as Research Development of 178.2 M, Total Operating Expenses of 548.3 M, Income Tax Expense of 2.5 M or Total Revenue of 785.1 M can show how well Tandem Diabetes Care performed in making a profits. Evaluating Tandem Diabetes income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Tandem Diabetes's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Tandem Diabetes Care latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Tandem Diabetes Care is a good buy for the upcoming year.
Tandem |
About Tandem Income Statement Analysis
Tandem Diabetes Care Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Tandem Diabetes shareholders. The income statement also shows Tandem investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Tandem Diabetes Income Statement Chart
Tandem Diabetes Care Income Statement is one of the three primary financial statements used for reporting Tandem's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Tandem Diabetes Care revenue and expense. Tandem Diabetes Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Tandem Diabetes' Gross Profit is very stable compared to the past year. As of the 23rd of April 2024, Cost Of Revenue is likely to grow to about 399 M, while Interest Expense is likely to drop about 5.8 M. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Tandem Diabetes Care. It is also known as Tandem Diabetes overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Tandem Diabetes' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Tandem Diabetes Care current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. At this time, Tandem Diabetes' Gross Profit is very stable compared to the past year. As of the 23rd of April 2024, Cost Of Revenue is likely to grow to about 399 M, while Interest Expense is likely to drop about 5.8 M.
| 2021 | 2023 | 2024 (projected) | Interest Expense | 4.3M | 7.6M | 5.8M | Depreciation And Amortization | 13.8M | 15.7M | 9.4M |
Tandem Diabetes income statement Correlations
Click cells to compare fundamentals
Tandem Diabetes Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Tandem Diabetes income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 6.1M | 10.5M | 13.8M | 31.0M | 15.7M | 9.4M | |
| Interest Expense | 7.6M | 78K | 12.2M | 4.3M | 7.6M | 5.8M | |
| Selling General Administrative | 165.7M | 204.9M | 261.5M | 335.7M | 352.5M | 370.1M | |
| Other Operating Expenses | 379.0M | 506.8M | 680.1M | 863.0M | 902.2M | 947.3M | |
| Operating Income | (16.7M) | (8.0M) | 8.8M | (61.8M) | (233.2M) | (221.6M) | |
| Ebit | (16.7M) | (8.0M) | 8.8M | (61.8M) | (133.9M) | (127.2M) | |
| Research Development | 45.2M | 63.6M | 92.1M | 139.1M | 169.7M | 178.2M | |
| Ebitda | (10.7M) | 2.5M | 22.7M | (30.8M) | (118.2M) | (112.3M) | |
| Total Operating Expenses | 210.9M | 268.5M | 353.6M | 474.8M | 522.2M | 548.3M | |
| Income Before Tax | (24.6M) | (36.3M) | 15.9M | (92.9M) | (220.3M) | (209.2M) | |
| Total Other Income Expense Net | (7.9M) | (28.3M) | 7.1M | (31.0M) | (78.8M) | (74.8M) | |
| Net Income | (24.8M) | (34.4M) | 15.6M | (94.6M) | (222.6M) | (211.5M) | |
| Income Tax Expense | 149K | (1.9M) | 335K | 1.7M | 2.4M | 2.5M | |
| Total Revenue | 362.3M | 498.8M | 702.8M | 801.2M | 747.7M | 785.1M | |
| Gross Profit | 194.2M | 260.5M | 376.2M | 413.0M | 367.7M | 386.1M | |
| Cost Of Revenue | 168.1M | 238.3M | 326.6M | 388.2M | 380.0M | 399.0M | |
| Net Income From Continuing Ops | (24.8M) | (34.4M) | 15.6M | (94.6M) | (222.6M) | (211.5M) | |
| Non Operating Income Net Other | (7.9M) | (28.3M) | (6.8M) | (4K) | (3.6K) | (3.8K) | |
| Net Income Applicable To Common Shares | (24.8M) | (34.4M) | 15.6M | (94.6M) | (108.8M) | (114.2M) | |
| Tax Provision | 149K | (1.9M) | 335K | 1.7M | 2.4M | 2.5M | |
| Interest Income | 3.3M | 1.6M | 674K | 6.1M | 22.9M | 24.0M | |
| Net Interest Income | 3.2M | (11.2M) | (5.4M) | (152K) | 13.0M | 13.6M | |
| Reconciled Depreciation | 6.1M | 10.5M | 13.8M | 14.3M | 15.7M | 11.5M |
Currently Active Assets on Macroaxis
When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Tandem Diabetes Care information on this page should be used as a complementary analysis to other Tandem Diabetes' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Tandem Stock analysis
When running Tandem Diabetes' price analysis, check to measure Tandem Diabetes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tandem Diabetes is operating at the current time. Most of Tandem Diabetes' value examination focuses on studying past and present price action to predict the probability of Tandem Diabetes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tandem Diabetes' price. Additionally, you may evaluate how the addition of Tandem Diabetes to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges |
Is Tandem Diabetes' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (3.43) | Revenue Per Share 11.509 | Quarterly Revenue Growth (0.11) | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.